# Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

> **NCT04061109** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 64 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Recombinant Human Coagulation FVIII

## Key facts

- **NCT ID:** NCT04061109
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-15
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061109, "Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04061109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*